Articles tagged "Highly-sensitized"

2019 American Transplant Congress
Bortezomib Based Induction Therapy Decreases Delayed Graft Function in High Risk Kidney Transplantation
K. Mahendran¹, N. Koizumi², J. K. Melancon¹
¹Transplant Institute, The George Washington University, Washington, DC, ²Schar School of Policy and Government, George Mason University, Arlington, VA
*Purpose: Over 100,000 candidates await a kidney transplant on the national United Network for Organ Sharing (UNOS) waitlist. Among these candidates, one-third have pre-formed antibodies…
2019 American Transplant Congress
Overcoming Anti-HLA Sensitization in Kidney Transplantation
R. C. Siqueira¹, P. Malafronte², J. C. Baptista-Silva², E. F. Silva², M. C. Camargo², M. C. Ribeiro Castro²
¹Nephrology Post-Graduation, University of Sao Paulo, São Paulo, Brazil, ²Kidney Transplant Unit, Hospital Samaritano de São Paulo, São Paulo, Brazil
*Purpose: To evaluate if it is possible to achieve good results in kidney transplantation (Ktx) regardless the degree of anti-HLA sensitization.*Methods: 143 adult living (LD)…
2019 American Transplant Congress
Prevention of Ischemia Reperfusion Injury (IRI) & ABMR in HLA Sensitized Patients Treated with C1 Esterase Inhibitor (C1INH): Long-Term Follow Up
A. A. Vo, E. Huang, N. Ammerman, J. Choi, I. Kim, A. Peng, R. Najjar, S. Sethi, K. Lim, S. C. Jordan
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Delayed graft function (DGF) after kidney transplantation is a consequence of IRI/DGF. IRI/DGF requires intense medical management, is costly and predisposes to risk for…
2019 American Transplant Congress
Outcomes after Incompatible Living Donor Kidney Transplantation in Older Recipients
J. Long¹, K. Jackson¹, J. Motter¹, S. Bae¹, A. Massie¹, M. Waldram¹, K. Covarrubias¹, J. Chen¹, B. Orandi², N. Desai¹, D. Segev¹, J. Garonzik-Wang¹
¹Johns Hopkins School of Medicine, Baltimore, MD, ²Surgery, University of Alabama at Birmingham, Birmingham, AL
*Purpose: Older individuals are the fastest-growing sub-group of transplant candidates who may face increased risks when considering incompatible living donor kidney transplantation (IKT) due to…
2019 American Transplant Congress
Differences in Wait Time, Graft Quality and Outcome for Pediatric Kidney Recipients in the Post-Kidney Allocation System Era
P. Singer, K. Eng, L. Castellanos Reyes, C. Sethna, L. Teperman, E. Grodstein
Northwell Health, Manhasset, NY
*Purpose: Though a purpose of the kidney allocation system (KAS) enacted in 2014 was to prioritize the transplantation of highly sensitized recipients, we explored the…
2019 American Transplant Congress
BK Virus Infection among Kidney Transplant Recipients with High Immunological Risk and Strong Immunosupression
G. Ledesma, M. O. Lopez, G. Carreño, M. J. Santana, M. A. Vaca, E. Gonzalez, C. Jimenez
Nephrology, Hospital Universitario La Paz, Madrid, Spain
*Purpose: BK virus infection represents one of the main viral infections within the first year after kidney transplantation, closely linked to the degree of immunosupresion.…
2019 American Transplant Congress
Autoantibody Production Significantly Decreased with APRIL/BLyS Blockade in Murine Chronic Rejection Kidney Transplant Model
N. Bath, X. Ding, B. Verhoven, S. Reese, N. Wilson, A. Sukhwal, R. Redfield III
University of Wisconsin, Madison, WI
*Purpose: Chronic antibody mediated rejection (cAMR) remains a significant barrier to achieving long-term graft survival in kidney transplantation. Alloantibody production from B lymphocytes and plasma…
2019 American Transplant Congress
Kidney & Pancreas Transplant Waitlist Management – A Tiered System Approach
H. L. Busch
Transplant, UCI Health, Orange, CA
*Purpose: Developed and implemented an innovative kidney & pancreas transplant waitlist management system in order to more effectively and efficiently re-evaluate patients on a transplant…
2019 American Transplant Congress
Long Term Outcomes Using Tocilizumab For The Treatment Of Chronic Antibody Mediated Rejection
J. Choi¹, E. Huang¹, O. Aubert², A. Vo¹, A. Peng¹, R. Najjar¹, S. Sethi¹, N. Ammerman¹, K. Lim¹, D. Puliyanda¹, A. Loupy², S. Jordan¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, ²Paris Translational Center for Organ Transplantation, Paris, France
*Purpose: Limited options exist for the treatment of kidney allograft rejection and preservation of allograft function. We reported our experience with anti-IL-6R (tocilizumab, TCZ) as…
2018 American Transplant Congress
Impact of De Novo DSA (DnDSA) on Outcomes in HLA-Sensitized (HS) Patients Transplanted after IVIG + Rituximab Desensitization (DES)
A. Vo,¹ O. Aubert,² H. Edmund,¹ A. Peng,¹ R. Najjar,¹ S. Supreet,¹ J. Choi,¹ K. Lim,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²Paris Translational Research Center for Organ Transplantation, Necker Hospital, Paris, France.
Introduction: Highly-HLA sensitized patients (HS) with donor specific antibodies (DSA) at transplant are at risk for Type 1 ABMR. However, the incidence of Type 2…

« Previous Page
1
…
5
6
7
8
9
…
15
Next Page »